FR2695556A1 - Compsn. contg. infinitesimal dilution of epidermal growth factor - stimulates normal cells but inhibits malignant ones and is useful in cosmetic and pharmaceutical compsns. - Google Patents
Compsn. contg. infinitesimal dilution of epidermal growth factor - stimulates normal cells but inhibits malignant ones and is useful in cosmetic and pharmaceutical compsns. Download PDFInfo
- Publication number
- FR2695556A1 FR2695556A1 FR9310820A FR9310820A FR2695556A1 FR 2695556 A1 FR2695556 A1 FR 2695556A1 FR 9310820 A FR9310820 A FR 9310820A FR 9310820 A FR9310820 A FR 9310820A FR 2695556 A1 FR2695556 A1 FR 2695556A1
- Authority
- FR
- France
- Prior art keywords
- egf
- cells
- dilutions
- growth factor
- epidermal growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000009024 Epidermal Growth Factor Human genes 0.000 title claims abstract description 41
- 239000012895 dilution Substances 0.000 title claims abstract description 27
- 238000010790 dilution Methods 0.000 title claims abstract description 27
- 230000003211 malignant effect Effects 0.000 title claims abstract description 10
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title claims abstract description 9
- 101800003838 Epidermal growth factor Proteins 0.000 title claims abstract description 7
- 229940116977 epidermal growth factor Drugs 0.000 title claims abstract description 7
- 239000002537 cosmetic Substances 0.000 title claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 13
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 230000001105 regulatory effect Effects 0.000 claims abstract description 3
- 210000001913 submandibular gland Anatomy 0.000 claims abstract description 3
- 238000009472 formulation Methods 0.000 claims abstract 2
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 claims description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 17
- 210000002510 keratinocyte Anatomy 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 9
- 210000002950 fibroblast Anatomy 0.000 abstract description 6
- 239000006210 lotion Substances 0.000 abstract description 6
- 239000000839 emulsion Substances 0.000 abstract description 4
- 239000002674 ointment Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 abstract 1
- 230000019522 cellular metabolic process Effects 0.000 abstract 1
- 102000005352 centromere protein F Human genes 0.000 abstract 1
- 108010031377 centromere protein F Proteins 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000002304 perfume Substances 0.000 description 11
- 230000010261 cell growth Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 241000233855 Orchidaceae Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- -1 flavorings Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229960002380 dibutyl phthalate Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- RZHBMYQXKIDANM-UHFFFAOYSA-N dioctyl butanedioate;sodium Chemical compound [Na].CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC RZHBMYQXKIDANM-UHFFFAOYSA-N 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UCSUOYMTZRJAIH-UHFFFAOYSA-N iron(2+) oxygen(2-) titanium(4+) Chemical compound [O-2].[O-2].[Ti+4].[Fe+2] UCSUOYMTZRJAIH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- YPMOZWCBANATQH-UHFFFAOYSA-N octyl 7-methyloctanoate Chemical compound CCCCCCCCOC(=O)CCCCCC(C)C YPMOZWCBANATQH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002943 palmitic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/002—Aftershave preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Abstract
Description
COMPOSITION BIOLOGIQUE CONTENANT DES EGF
DESTINEE A REGULER LA CROISSANCE CELLULAIRE
La présente invention a trait au domaine des produits dits facteurs de croissance et concerne plus spécialement de nouvelles applications de ces produits.BIOLOGICAL COMPOSITION CONTAINING EGF
FOR REGULATING CELL GROWTH
The present invention relates to the field of so-called growth factor products and more specifically relates to new applications of these products.
Les facteurs de croissance sont définis en biologie cellulaire comme des substances capables de stimuler la prolifération des cellules. Growth factors are defined in cell biology as substances capable of stimulating cell proliferation.
Un nombre important de facteurs de croissance d'origines diverses du type tissus ou organes animaux, sécrétions cellulaires, ont été identifiés, isolés et caractérisés. A large number of growth factors of various origins such as animal tissues or organs, cell secretions, have been identified, isolated and characterized.
On se référera plus spécialement ici au facteur de croissance épidermique dénommé EGF ("Epidermal Growth
Factor", selon la terminologie anglo-saxonne).We will refer more specifically here to the epidermal growth factor called EGF ("Epidermal Growth
Factor ", in Anglo-Saxon terminology).
Isolé depuis une trentaine d'années, 1'EGF est un polypeptide dont l'activité mitogène a été décrite dans de nombreux articles. Sa capacité à stimuler la prolifération des cellules de peau en culture a été mise en évidence dans le brevet FRA-2 472 385 et le certificat d'addition FRA-2 533 438, ainsi que son utilisation en cosmétologie à des doses de 0,001% à 0,1t. Isolated for around thirty years, EGF is a polypeptide whose mitogenic activity has been described in numerous articles. Its ability to stimulate the proliferation of skin cells in culture has been demonstrated in patent FRA-2,472,385 and the certificate of addition FRA-2,533,438, as well as its use in cosmetology at doses of 0.001% to 0.1t.
L'utilisation d'un tel facteur de croissance dans le cas d'organismes, présentant des risques de prolifération de cellules malignes s'avère potentiellement dangereuse du fait de la division anarchique des cellules dont le développement est favorisé par 1'EGF. The use of such a growth factor in the case of organisms presenting risks of proliferation of malignant cells proves to be potentially dangerous because of the uncontrolled division of cells whose development is favored by EGF.
Il a maintenant été trouvé, de manière surprenante que des doses extrêmement faibles de facteurs de croissance présentaient l'avantage de stimuler la multiplication des cellules saines tout en inhibant la prolifération des cellules malignes. It has now surprisingly been found that extremely low doses of growth factors have the advantage of stimulating the multiplication of healthy cells while inhibiting the proliferation of malignant cells.
Ainsi la présente invention a pour objet, une composition biologique permettant de réguler l'activité mitotique et métabolique par la stimulation des cellules normales en culture et l'inhibition des cellules malignes en culture, caractérisée en ce qu'elle renferme comme principe actif un facteur de croissance épidermique (EGF) en des quantités infinitésimales. Thus, the subject of the present invention is a biological composition making it possible to regulate the mitotic and metabolic activity by the stimulation of normal cells in culture and the inhibition of malignant cells in culture, characterized in that it contains as active ingredient a factor of epidermal growth (EGF) in infinitesimal quantities.
En pratique, on utilise l'EGF sous forme de dilutions successives réalisées à partir d'un solvant approprie. In practice, EGF is used in the form of successive dilutions made from an appropriate solvent.
A cet effet, on peut mettre en oeuvre tout solvant convenable. Dans la description qui suit, on décrit comme solvant particulièrement avantageux un mélange d'alcool et de glycérine. To this end, any suitable solvent can be used. In the description which follows, a particularly advantageous solvent is a mixture of alcohol and glycerin.
L'invention sera mieux comprise par la description résumée de nombreuses séries d'essais entrepris par la
Demanderesse et permettant d'établir l'efficacité des dilutions très élevées d'EGF dans la régulation de la croissance cellulaire.The invention will be better understood from the summary description of numerous series of tests undertaken by the
Applicant and allowing to establish the effectiveness of very high dilutions of EGF in the regulation of cell growth.
Exemples de réalisation
Les exemples qui suivent concernent tout d'abord l'action inhibitrice de dilutions d'EGF sur la croissance de kératinocytes malins, puis l'effet stimulant de ces mêmes dilutions sur la croissance de fibroblastes sains.Examples of realization
The examples which follow relate firstly to the inhibitory action of dilutions of EGF on the growth of malignant keratinocytes, then to the stimulating effect of these same dilutions on the growth of healthy fibroblasts.
Premier groupe d'essais
a) L'EGF utilisé dans le premier groupe d'essais provenait des glandes sous-maxillaires de la souris. En effet, de par sa structure similaire à 1'EGF humain, 1'EGF murin peut être utilisé chez l'homme.First group of tests
a) The EGF used in the first group of tests came from the submandibular glands of the mouse. Indeed, due to its structure similar to human EGF, murine EGF can be used in humans.
Il s'agit d'un polypeptide de 56 Acides aminés comprenant trois ponts disulfure, de poids moléculaire 6,045KD. It is a polypeptide of 56 amino acids comprising three disulfide bridges, of molecular weight 6.045KD.
b) Pour la réalisation des essais, on a procédé à des dilutions centésimales sériées d'EGF en utilisant comme solvant de l'éthanol à 20 degrés alcoolimétrique additionné de 25 % (en poids) de glycérine pure et en partant d'une solution mère contenant 0,01 mole.l-1 d'EGF. b) In order to carry out the tests, serial centesimal dilutions of EGF were carried out using 20% alcoholimetric ethanol as solvent containing 25% (by weight) of pure glycerin and starting from a stock solution. containing 0.01 mole.l-1 of EGF.
La gamme étalon a été obtenue comme suit : on a dilué, dans 3,5 ml de solvant, 35 l (microlitres) de solution mère en agitant pendant cinq minutes, ceci donnant un échantillon de concentration 10-4M. Puis 35y1 de cet échantillon ont été agités pendant cinq minutes avec 3,5 ml de solvant pour donner une nouvelle dilution de concentration 10-6M. On a ensuite opéré de la même façon pour obtenir les dilutions successives au 1/100 ème, de concentration 10-8Mt 10-10M ... l060M. Chacune des dilutions a été conservée à +40C et des séries de gammes témoins ont été réalisées, selon les mêmes dilutions, en utilisant uniquement le solvant précité. The standard range was obtained as follows: 35 l (microliters) of stock solution were diluted in 3.5 ml of solvent, with stirring, for five minutes, giving a sample of 10-4M concentration. Then 35 µl of this sample was stirred for five minutes with 3.5 ml of solvent to give a further 10-6M concentration dilution. We then operated in the same way to obtain successive dilutions to 1/100 th, concentration 10-8Mt 10-10M ... l060M. Each of the dilutions was stored at + 40C and series of control ranges were made, according to the same dilutions, using only the aforementioned solvent.
Bien entendu, on a réalisé selon le même principe de dilution, des solutions de concentration : 10-5M, 10-7M ... 10-59M à partir d'un échantillon de concentration 10-3M, ainsi que les dilutions intermédiaires.Of course, the same dilution principle was used to produce concentration solutions: 10-5M, 10-7M ... 10-59M from a 10-3M concentration sample, as well as the intermediate dilutions.
c) Les cellules mises en oeuvre dans le premier groupe d'essais étaient des kératinocytes de lignée provenant d'un carcinome squameux murin. Les kératinocytes ont été cultivés dans un milieu de culture approprié. Afin d'optimiser les conditions expérimentales, les expériences ont été réalisées sur un milieu de culture carencé en sérum de veau foetal (SVF), c'est-à-dire ayant une teneur en SVF de 2% au lieu du taux d'environ 10% généralement nécessaire. c) The cells used in the first group of tests were line keratinocytes originating from a squamous murine carcinoma. The keratinocytes were cultured in an appropriate culture medium. In order to optimize the experimental conditions, the experiments were carried out on a culture medium deficient in fetal calf serum (SVF), that is to say having an SVF content of 2% instead of the rate of approximately 10% generally required.
d) Les essais proprement dits ont été faits en comparant le taux de croissance cellulaire de kératinocytes mis en présence de dilutions successives d'EGF au taux de croissance cellulaire d'échantillons témoins constitués d'une part par les kératinocytes seuls et d'autre part par les kératinocytes mis en présence du solvant, dilué sur lui-même dans les mêmes conditions. d) The tests themselves were carried out by comparing the cell growth rate of keratinocytes placed in the presence of successive dilutions of EGF with the cell growth rate of control samples constituted on the one hand by the keratinocytes alone and on the other hand by the keratinocytes placed in the presence of the solvent, diluted on itself under the same conditions.
Pour cela, on a travaillé selon un protocole opératoire bien déterminé, les kératinocytes ayant été répartis en trois groupes
Le premier ayant reçu la dilution à tester, le second ayant reçu le solvant, le troisième constitué par les kératinocytes seuls.To do this, we worked according to a well-defined operating protocol, the keratinocytes having been divided into three groups
The first having received the dilution to be tested, the second having received the solvent, the third consisting of keratinocytes alone.
Après le deuxième jour de mise en contact, on a procédé au dénombrement des kératinocytes, en utilisant la technique au bleu de méthylène (culture sur plaques à six puits). After the second day of contacting, the keratinocytes were counted, using the methylene blue technique (culture on six-well plates).
Ces mesures ont été répétées au troisième jour après inoculation et elles ont permis de calculer le taux de croissance cellulaire pour les échantillons à tester et les deux échantillons témoins. These measurements were repeated on the third day after inoculation and they made it possible to calculate the cell growth rate for the test samples and the two control samples.
En comparant les taux de croissance pour le groupe à tester et les deux groupes témoins on a pu constater une différence très significative entre les deux séries de valeurs. By comparing the growth rates for the group to be tested and the two control groups, a very significant difference between the two series of values was observed.
e) Dans la première série d'essais on a mis en oeuvre des dilutions infinitésimales d'EGF de 10-9M, 10-15M, 10-19M, 10-25M, 10-35M, 1045M, et 1055M. e) In the first series of tests, infinitesimal dilutions of EGF of 10-9M, 10-15M, 10-19M, 10-25M, 10-35M, 1045M, and 1055M were used.
Les résultats des essais sont illustrés par les graphiques annexés quireprésentent - Figure 1 : Un diagramme de taux de croissance cellulaire dans lequel chaque pic représente le taux de croissance cellulaire de kératinocytes traités au deuxième jour après inoculation. Les pics TC et TS correspondant respectivement aux témoins constitués par les cellules seules et les cellules mises au contact du solvant. The results of the tests are illustrated by the attached graphs which represent - Figure 1: A cell growth rate diagram in which each peak represents the cell growth rate of keratinocytes treated on the second day after inoculation. The TC and TS peaks respectively correspond to the controls constituted by the cells alone and the cells brought into contact with the solvent.
En abcisse, sont portées les concentrations des dilutions infinitésimales d'EGF exprimées en concentration molaire (M) et en ordonnée, le taux de croissance cellulaire mesuré sous forme de densité optique, suite à la coloration au bleu de méthylène. The abscissa shows the concentrations of the infinitesimal dilutions of EGF expressed in molar concentration (M) and on the ordinate, the cell growth rate measured in the form of optical density, following staining with methylene blue.
- Figure 2 : Un diagramme de taux de croissance cellulaire au troisième jour après inoculation.- Figure 2: A diagram of cell growth rate on the third day after inoculation.
I1 ressort clairement des figures 1 et 2, que 1'EGF exerce un puissant effet inhibiteur sur la prolifération des cellules malignes. It is clear from Figures 1 and 2 that EGF exerts a powerful inhibitory effect on the proliferation of malignant cells.
f) D'autres séries d'essais ont été réalisées avec des dilutions infinitésimales d'EGF de 1020M, 1040M et 10-60M. Ces essais ont conduit aux mêmes effets, c'est-à-dire une inhibition significative de la croissance de kératinocytes de lignée à toutes les dilutions testées. f) Other series of tests have been carried out with infinitesimal dilutions of EGF of 1020M, 1040M and 10-60M. These tests led to the same effects, that is to say a significant inhibition of the growth of lineage keratinocytes at all the dilutions tested.
Deuxième groupe d'essais
a) L'EGF utilisé dans le deuxième groupe d'essais était l'EGF humain recombinant à 98% de pureté (Sigma E 3264).Second group of tests
a) The EGF used in the second group of tests was 98% purity recombinant human EGF (Sigma E 3264).
b) Pour la réalisation des essais, on a procédé de la même manière que dans le premier groupe d'essais, à des dilutions centésimales sériées d'EGF. b) In order to carry out the tests, the same method was used as in the first group of tests, in serial centesimal dilutions of EGF.
c) Les cellules mises en oeuvre dans le deuxième groupe d'essais étaient des fibroblastes humains de premier explant, cultivés selon la technique décrite dans le premier groupe d'essais. c) The cells used in the second group of tests were human fibroblasts of the first explant, cultured according to the technique described in the first group of tests.
d) Le protocole opératoire des essais a différé de celui du premier groupe dans la mesure où le dénombrement des fibroblastes a été effectué en utilisant la technique au bleu de méthylène (culture sur plaques renfermant 96 puits). Le dénombrement a été répété au quatrième, cinquième et sixième jour après inoculation. d) The operating protocol for the trials differed from that of the first group insofar as the fibroblast count was carried out using the methylene blue technique (culture on plates containing 96 wells). The count was repeated on the fourth, fifth and sixth day after inoculation.
e) Dans la première série d'essais, on a mis en oeuvre des dilutions infinitésimales d'EGF 10-7M, l09M, 10-15M, 10-19M, 10-25M, 10-35M, 10-45M et 10-55M. e) In the first series of tests, infinitesimal dilutions of EGF 10-7M, l09M, 10-15M, 10-19M, 10-25M, 10-35M, 10-45M and 10-55M were used. .
Les résultats des essais sont illustrés par le graphique annexé qui représente. The results of the tests are illustrated by the attached graph which represents.
- Figure 3 : Un diagramme de taux de croissance cellulaire, dans lequel chaque pic représente comme dans les figures précédentes le taux de croissance cellulaire de fibroblastes traités au sixième jour après inoculation.- Figure 3: A cell growth rate diagram, in which each peak represents, as in the previous figures, the cell growth rate of fibroblasts treated on the sixth day after inoculation.
I1 ressort clairement de la Figure 3, que 1'EGF exerce un effet stimulateur sur la croissance des fibroblastes normaux. It is clear from Figure 3 that EGF exerts a stimulatory effect on the growth of normal fibroblasts.
f) D'autres séries d'essais ont été réalisées avec des dilutions infinitésimals d'EGF de 10-20M, 1030M 10-60M. f) Other series of tests have been carried out with infinitesimal dilutions of EGF of 10-20M, 1030M 10-60M.
Ces essais ont conduit aux mêmes effets, c'est-à-dire une stimulation de la division des cellules à toutes les dilutions testées. These tests led to the same effects, that is to say a stimulation of the division of cells at all the dilutions tested.
La composition biologique selon l'invention pouvant être destinée à un usage pharmaceutique ou cosmétique, contient bien entendu, outre le principe actif susvisé, les excipients et adjuvants habituels tels que épaississants, diluants, solvants, émulsifiants, lubrifiants, aromatisants, liants etc...., formulés en fonction de leur mode d'administration. The biological composition according to the invention which may be intended for pharmaceutical or cosmetic use, of course contains, in addition to the abovementioned active principle, the usual excipients and adjuvants such as thickeners, diluents, solvents, emulsifiers, lubricants, flavorings, binders, etc. .., formulated according to their mode of administration.
Les compositions selon l'invention pourront prendre les formes les plus variées, convenant à l'application topique, notamment : pommades, lotions, émulsions, onguents, gels ou autres. The compositions according to the invention may take the most varied forms, suitable for topical application, in particular: ointments, lotions, emulsions, ointments, gels or the like.
A titre d'exemple, on peut citer les compositions suivantes. By way of example, the following compositions may be mentioned.
Exemple 1
Emulsion régénératrice : % (en poids) Propylèneglycol 5,0 Carbopol 934 .... 0,6 Alcool cétylique ... 1,0 Dérivés de lanoline .... 10,00 Huiles végétales ... 7,0 Myristate d'Isopropyle ... 10,00
Triethanolamina... 0,6 & Tocophérol... 0,05
EGF - (Solution 10-10M)... 10,00 Conservateurs 0,15
Parfum... 0,2 Eau démineralisée et stérilisée q.s pour 100
Exemple 2
Lotion : % (en poids) Extrait hydroglycolique végétal (*) ... 5-10
Glycérine... 2-5
EDTA (sel disodique)... 0,05 Acide lactique ... 0,50
Urée 0,25 Lactate de Na (Sol. 70%) ... 0,50 .Pyrrolidone carboxylate de sodium (sol. 50%). 0,75 Conservateurs 0,25 EGF - (Solution.l0-19M) 10,00
Parfum 0,20 Eau déminéralisée et stérilisée q.s pour 100 (*) Camomille, Gentella Asiatica, Orchidée, Lotus,
Ginseng. Example 1
Regenerative emulsion:% (by weight) Propylene glycol 5.0 Carbopol 934 .... 0.6 Cetyl alcohol ... 1.0 Lanolin derivatives .... 10.00 Vegetable oils ... 7.0 Myristate Isopropyl ... 10.00
Triethanolamina ... 0.6 & Tocopherol ... 0.05
EGF - (10-10M solution) ... 10.00 Preservatives 0.15
Perfume ... 0.2 Demineralized and sterilized water qs per 100
Example 2
Lotion:% (by weight) Vegetable hydroglycolic extract (*) ... 5-10
Glycerin ... 2-5
EDTA (disodium salt) ... 0.05 Lactic acid ... 0.50
Urea 0.25 Na lactate (Sol. 70%) ... 0.50. Sodium pyrrolidone carboxylate (sol. 50%). 0.75 Preservatives 0.25 EGF - (Solution.l0-19M) 10.00
Perfume 0.20 Demineralized and sterilized water qs per 100 (*) Chamomile, Gentella Asiatica, Orchid, Lotus,
Ginseng.
Exemple 3
Masque Stimulant : % (en poids)
Kaolin 5,0 Lait en poudre ....... 2,0
Talc 12,0
Stearaklonium Bentonite... 8,0
Glycérine 10,0 Propylène Glycol ..... 10,0 Alcool Polyvinylique ... 0,5 ... Dioctyl Succinate de Sodium 0,5 Conservateurs 0,150
EGF (Solution.10-11M)... 10,0
Parfum 0,35 Eau déminéralisée et stérilisée q.s pour 100
Exemple 4
Pommade Labiale régénérante : % (en poids) Ceresine 5-7 Cire de Carnauba ... 5-7
Ozokérite 3-5 Alcools de Lanoline .... 20-23 PPG 45 Dodecyl glycol Copolymer ... 18-22 Lactate de Myristyle ... 18-22 Complexe Cire d'abeille PEG 20 - Sorbitol .. 5-7 Huiles Végétales ... 3-5 Bentone 0,4-0,6
Glycérine 3-5 Conservateurs 0,25-0,30
EGF (Solution 10-9M)... 10,00 , Eau déminéralisée et stérilisée q.s pour 100
Exemple 5
Fond de Teint traitant Propylèneglycol 5-8 . Poudre de Soie naturelle....... 1-2 . Carboxy Méthyl Cellulose de Na... 0,2-0,3 . Talc........ 1,0-2,0 .Oxydes de Ti, Fe (rouge, jaune, brun, noir) . q.s pour
teinte . Mono, di-Stéarate de 1, 2 propanediol 1,5-2,0 . Mélanges d'acides stéarique et palmitique ... 1,5-2,5 . Lanolate d'Isopropyle... 1,0-2,0 . Dérivés de Lanoline... 0,5-1,0 . Huiles végétales... 3-5
Lécithine de Soja ...... 0,5-1,0
& Tocopherol... 0,05 . EGF (Solution 10-17M)... 5-10 . Conservateurs... 0,35 , parfum < 0,35 , Eau déminéralisée et stérilisée q.s pour 100
Exemple 6
Emulsion dermatologique apaisante % (en poids) (brûlures, erythemes) : . Stearate de Propylèneglycol... 5,0-7,0 . Cire de Paraffine... 1,0-2,0 Huile de Paraffine ........... 3,0-5,0 . Stearine..... 3,0-4,0 . Glycérine... 3,0-5,0 . Huiles végétales... 3,0-5,0 . Allantoine......... 0,2-0,5 . Extrait hydroglycolique de camomille 2,0-4,0 . & Bisabolol... 0,1-0,3 . Triethanolamine..... 0,5-0,75 .EGF (Solution 10-9M)... 5-10 . Conservateurs... 0,25-0,50 . Parfum.... 0,25-0,50 , Eau Déminéralisée et stérilisée q.s pour 100
Exemple 7
Lotion Après Rasage . Acide lactique.... 0,3-0,5 . Lactate de Na.... 0,2-0,4 . Glycérine... 1,05-3,0 . Allantoine... 0,15-0,35 EDTA (Solution disodique) 0,05 . Carboxymethyl Cellulose... 0,05-0,15 . EGF (Solution 10-15M)... 5-10 . Conservateurs... 0,20-0,35 . Parfum... 0,20-0,35 , Colorant q.s pour teinte , Eau déminéralisée et stérilisée q.s pour 100
Exemple 8
Crème réparatrice pour les ongles : % (en poids) Propylène-Glycol 3,0-5,0
Carboxyméthyl cellulose .......... 0,1-0,3
Triéthanolamine... 1,5-2,5
Monostéarate de glycérol ... 1,0-3,0
Acide Stéarique/Palmitique ... 2,0-3,0
Triglycérides C8 - C12 (huile végétale) ... 8,0-10,0
Huile de Vaseline légère .... 3,0-5,0
Myristate d'Isopropyle ... 1,0-3,0
Huile de Lanoline ... 1,0-3,0
EGF (Solution 1019M) ...... 5,0-10,0
Conservateurs... 0,15-0,30
Parfum... 0,20-0,35
Eau déminéralisée et distillée q.s pour 100
Exemple 9
Gel traitant pour les ongles : % (en poids)
Carpobol 934 ... 0,3-0,4
Carboxméthyl Cellulose ... 0,1-0,3
Triéthanolamine... 0,3-0,5
Urée..... 0,1-0,3
Propyléne Glycol...... 8,0-12,0
EGF (Solution 10-19 M) ...... 5,0-10,0
Conservateurs... 0,15-0,25
Parfum... 0,20-0,35
Eau déminéralisée et distillée q.s pour 100
Exemple 10
Base incolore traitante : % (en poids)
Nitrocellulose RS 1/2 sec ... 10,0-15,0
Résine de Toluène Sulfonamide/
Formaldéhyde (Santolite) ... 5,0-10,0
Phtalate de Butyle ... 3,0-4,0
Acétate de n-Butyle ... 27,0-33,0
Alcool n-Butylique ... 1,0-2,0
Alcool éthylique 96 % ... 5,0-7,5
EGF (Solution alc. 10-19 M) ... 5,0-10,0
Toluène q.s pour 100
Exemple 11
Vernis laqué nacré traitant : % (en poids) a) Base
Nitrocellulose RS 1/2 Sec ... 13,0-19,0
Résine de Toluène Sulfonamide/
Formaldéhyde (Santolite) ... 5,0-9,0
Phtalate de Butyle ... 2,0-4,0
Acétate de n-Butyle ... 14,0-18,0
Acétate d'Ethyle ... 12,0-16,0
Alcool Ethylique 96 % ... 6,0-9,0
EGF (solution alc. 10-19 M) ... 5,0-10,0
Toluène q.s pour 100 b) Vernis coloré nacré
Base (ci-dessus) ... 97,0
Pigments autorisés
(DC Red 6/30/36/9/7,
FDC Yellow 5/6)
Oxyde de Fer
Oxyde de Titane q.s
Nacre :Guanine, Oxychlorure
de Bismuth q.s
Stéraralkonium Hectorite q.s pour 100
(Bentone 27/38)
Exemple 12
Lotion Tonique Cheveux Normaux
Alcool 96 % ... 50,00-60,00
Extrait Hydro Lotus ... 1,00-3,00
Extrait Hydro Orchidée ... 1,00-3,00
Tocophéryl Acétate ... 0,01-0,05
EGF (solution alc. 10-19 M) ... 5,00-10,00
Parfum... 0,10-0,30
Colorants - q.s
Eau déionisée q.s pour 100
Exemple 13
Lotion Tonique Cheveux Fragiles
Diméthicone... 3,00-8,00
Extrait Lipo Lotus ... 1,00-3,00
Extrait Lipo Orchidée ... 1,00-3,00
CIS, CIS Linoléate d'Ethyle ... 2,00-5,00
EGF (solution alc. 10-19 M) ... 4,00-8,00
Parfum... 0,10-0,30
Colorants q.s
Diméthiconol q.s pour 100
Exemple 14
Lotion Tonique Traitante
Cyclométhicone... 25,00-35,00
Isononanoate d'Octyle ... 2,00-5,00
Alcool cétylique éthoxyle 20, propoxyle 5 ... 1,00-3,00
Extrait Lipo Lotus ... 0,50-1,00
Extrait Lipo Orchidée ... 0,50-1,00
EGF (solution alc. 10-19 M) ... 5,00-10,00
Parfum... 0,10-0,30
Colorants q. s
Alcool éthylique 96 % q.s pour 100 Example 3
Stimulating Mask:% (by weight)
Kaolin 5.0 Milk powder ....... 2.0
Talc 12.0
Stearaklonium Bentonite ... 8.0
Glycerin 10.0 Propylene Glycol ..... 10.0 Polyvinyl Alcohol ... 0.5 ... Sodium Dioctyl Succinate 0.5 Preservatives 0.150
EGF (Solution.10-11M) ... 10.0
Perfume 0.35 Demineralized and sterilized water qs per 100
Example 4
Regenerating Labial Ointment:% (by weight) Ceresine 5-7 Carnauba wax ... 5-7
Ozokerite 3-5 Lanolin Alcohols .... 20-23 PPG 45 Dodecyl glycol Copolymer ... 18-22 Myristyl Lactate ... 18-22 Beeswax Complex PEG 20 - Sorbitol .. 5-7 Vegetable Oils ... 3-5 Bentone 0.4-0.6
Glycerin 3-5 Preservatives 0.25-0.30
EGF (Solution 10-9M) ... 10.00, Demineralized and sterilized water qs per 100
Example 5
Foundation treating Propylene glycol 5-8. Natural Silk Powder ....... 1-2. Carboxy Methyl Cellulose Na ... 0.2-0.3. Talc ........ 1.0-2.0. Ti, Fe oxides (red, yellow, brown, black). qs for
tint. Mono, di-stearate of 1,2 propanediol 1,5-2,0. Mixtures of stearic and palmitic acids ... 1.5-2.5. Isopropyl Lanolate ... 1.0-2.0. Lanolin derivatives ... 0.5-1.0. Vegetable oils ... 3-5
Soy lecithin ...... 0.5-1.0
& Tocopherol ... 0.05. EGF (Solution 10-17M) ... 5-10. Preservatives ... 0.35, perfume <0.35, Demineralized and sterilized water qs per 100
Example 6
Soothing dermatological emulsion% (by weight) (burns, erythemes):. Propylene glycol stearate ... 5.0-7.0. Paraffin wax ... 1.0-2.0 Paraffin oil ........... 3.0-5.0. Stearine ..... 3.0-4.0. Glycerin ... 3.0-5.0. Vegetable oils ... 3.0-5.0. Allantoin ......... 0.2-0.5. Hydroglycolic chamomile extract 2.0-4.0. & Bisabolol ... 0.1-0.3. Triethanolamine ..... 0.5-0.75 .EGF (10-9M Solution) ... 5-10. Preservatives ... 0.25-0.50. Perfume .... 0.25-0.50, Demineralized and sterilized water qs per 100
Example 7
Aftershave . Lactic acid .... 0.3-0.5. Na lactate .... 0.2-0.4. Glycerin ... 1.05-3.0. Allantoin ... 0.15-0.35 EDTA (Disodium solution) 0.05. Carboxymethyl Cellulose ... 0.05-0.15. EGF (Solution 10-15M) ... 5-10. Preservatives ... 0.20-0.35. Perfume ... 0.20-0.35, Colorant qs for color, Demineralized and sterilized water qs for 100
Example 8
Repairing nail cream:% (by weight) Propylene-Glycol 3.0-5.0
Carboxymethyl cellulose .......... 0.1-0.3
Triethanolamine ... 1.5-2.5
Glycerol monostearate ... 1.0-3.0
Stearic / Palmitic Acid ... 2.0-3.0
Triglycerides C8 - C12 (vegetable oil) ... 8.0-10.0
Light Vaseline oil .... 3.0-5.0
Isopropyl myristate ... 1.0-3.0
Lanolin oil ... 1.0-3.0
EGF (Solution 1019M) ...... 5.0-10.0
Preservatives ... 0.15-0.30
Perfume ... 0.20-0.35
Demineralized and distilled water qs per 100
Example 9
Treating gel for nails:% (by weight)
Carpobol 934 ... 0.3-0.4
Carboxmethyl Cellulose ... 0.1-0.3
Triethanolamine ... 0.3-0.5
Urea ..... 0.1-0.3
Propylene Glycol ...... 8.0-12.0
EGF (Solution 10-19 M) ...... 5.0-10.0
Preservatives ... 0.15-0.25
Perfume ... 0.20-0.35
Demineralized and distilled water qs per 100
Example 10
Colorless treating base:% (by weight)
Nitrocellulose RS 1/2 sec ... 10.0-15.0
Toluene Sulfonamide resin /
Formaldehyde (Santolite) ... 5.0-10.0
Butyl phthalate ... 3.0-4.0
N-Butyl acetate ... 27.0-33.0
N-Butyl alcohol ... 1.0-2.0
Ethyl alcohol 96% ... 5.0-7.5
EGF (Solution alc. 10-19 M) ... 5.0-10.0
Toluene qs per 100
Example 11
Pearl lacquer varnish treating:% (by weight) a) Base
Nitrocellulose RS 1/2 Sec ... 13.0-19.0
Toluene Sulfonamide resin /
Formaldehyde (Santolite) ... 5.0-9.0
Butyl phthalate ... 2.0-4.0
N-Butyl acetate ... 14.0-18.0
Ethyl acetate ... 12.0-16.0
Ethyl Alcohol 96% ... 6.0-9.0
EGF (solution alc. 10-19 M) ... 5.0-10.0
Toluene qs for 100 b) Pearly colored varnish
Base (above) ... 97.0
Permitted pigments
(DC Red 6/30/36/9/7,
FDC Yellow 5/6)
Iron oxide
Titanium oxide qs
Mother-of-pearl: Guanine, Oxychloride
from Bismuth qs
Steraralkonium Hectorite qs per 100
(Bentone 27/38)
Example 12
Normal Hair Toning Lotion
Alcohol 96% ... 50.00-60.00
Hydro Lotus extract ... 1.00-3.00
Hydro Orchid extract ... 1.00-3.00
Tocopheryl Acetate ... 0.01-0.05
EGF (solution alc. 10-19 M) ... 5.00-10.00
Perfume ... 0.10-0.30
Dyes - qs
Deionized water qs per 100
Example 13
Tonic Lotion for Fragile Hair
Dimethicone ... 3.00-8.00
Lipo Lotus extract ... 1.00-3.00
Lipo Orchid extract ... 1.00-3.00
CIS, CIS Ethyl Linoleate ... 2.00-5.00
EGF (solution alc. 10-19 M) ... 4.00-8.00
Perfume ... 0.10-0.30
Dyes qs
Dimethiconol qs per 100
Example 14
Tonic Treatment Lotion
Cyclomethicone ... 25.00-35.00
Octyl isononanoate ... 2.00-5.00
Cetyl alcohol ethoxyl 20, propoxyl 5 ... 1.00-3.00
Lipo Lotus extract ... 0.50-1.00
Lipo Orchid extract ... 0.50-1.00
EGF (solution alc. 10-19 M) ... 5.00-10.00
Perfume ... 0.10-0.30
Dyes q. s
Ethyl alcohol 96% qs per 100
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9310820A FR2695556B1 (en) | 1992-09-15 | 1993-09-10 | Biological composition containing EGF intended to regulate cell growth. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9210994A FR2695557A1 (en) | 1992-09-15 | 1992-09-15 | Compsn. contg. infinitesimal dilution of epidermal growth factor |
| FR9310820A FR2695556B1 (en) | 1992-09-15 | 1993-09-10 | Biological composition containing EGF intended to regulate cell growth. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2695556A1 true FR2695556A1 (en) | 1994-03-18 |
| FR2695556B1 FR2695556B1 (en) | 1995-03-24 |
Family
ID=26229726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9310820A Expired - Fee Related FR2695556B1 (en) | 1992-09-15 | 1993-09-10 | Biological composition containing EGF intended to regulate cell growth. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2695556B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0776175A1 (en) * | 1994-03-31 | 1997-06-04 | Biomed Comm Incorporated | Therapeutic homeopathic dilutions of growth factors and methods of their use |
| US6024734A (en) * | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
| WO2006126212A2 (en) | 2005-05-27 | 2006-11-30 | Bharat Biotech International Limited | Epidermal growth factor composition, a process therefor and its application |
| FR3000676A1 (en) * | 2013-01-10 | 2014-07-11 | Oreal | Composition, useful for dyeing human keratin fibers, preferably hair, comprises oxidation dye precursor e.g. phenylenediamines, and oil extract of lotus flower obtained form e.g. Nelumbium speciosum |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS615006A (en) * | 1984-06-19 | 1986-01-10 | Sanki Shoji Kk | Agent for skin |
| EP0205051A1 (en) * | 1985-05-30 | 1986-12-17 | ZAMBON S.p.A. | A pharmaceutical composition in the form of a cream for dermal and ophthalmic use |
| JPS6219511A (en) * | 1985-07-19 | 1987-01-28 | Kanebo Ltd | Cosmetic for preventing aging of skin |
| EP0224885A1 (en) * | 1985-11-28 | 1987-06-10 | Wakunaga Seiyaku Kabushiki Kaisha | Antitumor composition. |
| EP0313515A1 (en) * | 1987-10-01 | 1989-04-26 | Ciba-Geigy Ag | A polypeptide growth factor from milk |
| EP0339905A2 (en) * | 1988-04-25 | 1989-11-02 | Ethicon, Inc. | Wound healing compositions containing growth factors and retinoids |
| JPH0249734A (en) * | 1988-08-12 | 1990-02-20 | Wakunaga Pharmaceut Co Ltd | Novel composition |
| JPH0429916A (en) * | 1990-05-24 | 1992-01-31 | Shiseido Co Ltd | External drug for skin |
-
1993
- 1993-09-10 FR FR9310820A patent/FR2695556B1/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS615006A (en) * | 1984-06-19 | 1986-01-10 | Sanki Shoji Kk | Agent for skin |
| EP0205051A1 (en) * | 1985-05-30 | 1986-12-17 | ZAMBON S.p.A. | A pharmaceutical composition in the form of a cream for dermal and ophthalmic use |
| JPS6219511A (en) * | 1985-07-19 | 1987-01-28 | Kanebo Ltd | Cosmetic for preventing aging of skin |
| EP0224885A1 (en) * | 1985-11-28 | 1987-06-10 | Wakunaga Seiyaku Kabushiki Kaisha | Antitumor composition. |
| EP0313515A1 (en) * | 1987-10-01 | 1989-04-26 | Ciba-Geigy Ag | A polypeptide growth factor from milk |
| EP0339905A2 (en) * | 1988-04-25 | 1989-11-02 | Ethicon, Inc. | Wound healing compositions containing growth factors and retinoids |
| JPH0249734A (en) * | 1988-08-12 | 1990-02-20 | Wakunaga Pharmaceut Co Ltd | Novel composition |
| JPH0429916A (en) * | 1990-05-24 | 1992-01-31 | Shiseido Co Ltd | External drug for skin |
Non-Patent Citations (6)
| Title |
|---|
| EPPSTEIN ET AL.: "epidermal growth factor receptor occupancy inhibits vaccinia virus infection", NATURE, vol. 318, no. 6047, December 1985 (1985-12-01), LONDON GB, pages 663 - 665 * |
| PATENT ABSTRACTS OF JAPAN vol. 10, no. 144 (C - 349)<2201> * |
| PATENT ABSTRACTS OF JAPAN vol. 11, no. 193 (C - 430)<2640> * |
| PATENT ABSTRACTS OF JAPAN vol. 14, no. 215 (C - 716)<4158> * |
| PATENT ABSTRACTS OF JAPAN vol. 16, no. 194 (C - 938) * |
| S.T.N., Serveur de Bases de Données, KARLSRUHE, DE, Fichier Chemical Abstracts vol 108, n 210007g & JP-A-62263115 (SHISEIDO) * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0776175A1 (en) * | 1994-03-31 | 1997-06-04 | Biomed Comm Incorporated | Therapeutic homeopathic dilutions of growth factors and methods of their use |
| US6024734A (en) * | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
| EP0776175A4 (en) * | 1994-03-31 | 2001-02-21 | Biomed Comm Inc | Therapeutic homeopathic dilutions of growth factors and methods of their use |
| WO2006126212A2 (en) | 2005-05-27 | 2006-11-30 | Bharat Biotech International Limited | Epidermal growth factor composition, a process therefor and its application |
| WO2006126212A3 (en) * | 2005-05-27 | 2007-07-12 | Bharat Biotech Int Ltd | Epidermal growth factor composition, a process therefor and its application |
| US8481049B2 (en) | 2005-05-27 | 2013-07-09 | Bharat Biotech International Limited | Methods for treating a wound using epidermal growth factor formulation |
| US8754043B2 (en) | 2005-05-27 | 2014-06-17 | Bharat Biotech International Limited | Epidermal growth factor compositions |
| FR3000676A1 (en) * | 2013-01-10 | 2014-07-11 | Oreal | Composition, useful for dyeing human keratin fibers, preferably hair, comprises oxidation dye precursor e.g. phenylenediamines, and oil extract of lotus flower obtained form e.g. Nelumbium speciosum |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2695556B1 (en) | 1995-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0862910B1 (en) | Use of retinoids as skin pigmentation inducing agent | |
| EP0892642B1 (en) | Use in a composition of an extract of at least one labiate of the genus rosmarinarus, cultured in vitro | |
| EP1337234B1 (en) | Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling | |
| EP0706368B1 (en) | Anti-acne composition containing a poria cocos wolf extract | |
| FR2768927A1 (en) | USE OF ELLAGIC ACID, ITS SALTS, ITS METAL COMPLEXES, ITS MONO- OR POLYMERIC, MONO- OR POLYACYLATED DERIVATIVES IN THE FIELD OF COSMETICS AND PHARMACY, IN PARTICULAR DERMATOLOGY | |
| FR2880802A1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT | |
| EP0997140A1 (en) | Skin and/or hair whitening composition | |
| FR2671487A1 (en) | USE OF A GROWTH FACTOR IN A SLIMMING COMPOSITION. | |
| EP0829260B1 (en) | Use of at least one pyrimidine derivative substituted in position 6 as stimulant of tyrosinase | |
| EP1837013A1 (en) | Composition comprising hydroxyapatite and a calcium salt for reinforcing the barrier function of the skin and/or semi-mucus membranes. | |
| FR2844715A1 (en) | Cosmetic, pharmaceutical or food supplement compositions, comprising resveratrol oligomer or derivative, optionally as plant extract, useful for combating disorders of skin or exoskeleton, e.g. acne or dry skin | |
| JP2003063985A (en) | Composition for cosmetic or the skin containing elastase- inhibiting compound of n-acylaminoamido family and at least one anti-inflammatory compound | |
| WO2001082940A1 (en) | Plant extract of the olea europaea species as no-synthase inhibitor and uses | |
| EP1278508A1 (en) | Plant extract of the species i vitis vinifera /i as no-synthase inhibitor and uses | |
| EP0790053A1 (en) | Use of 2-amino-alkane-1,3-diol to reduce hairloss and/or to induce and stimulate hairgrowth | |
| FR2755367A1 (en) | USE OF AN ERECTA POTENTIAL EXTRACT IN THE FIELD OF COSMETICS AND PHARMACY, ESPECIALLY DERMATOLOGY | |
| WO2008071897A2 (en) | Topical use of at least one monounsaturated fatty acid to improve hair | |
| EP1337233B1 (en) | Use of at least a sulphonic amino derivative in a composition promoting skin peeling | |
| FR2722100A1 (en) | PERVENCHE SEED EXTRACT AND COMPOSITION CONTAINING SAME | |
| CA2322149A1 (en) | Use of a compound inhibiting the activity of a sodium channel and a calcium channel in a composition for topical use | |
| FR2695556A1 (en) | Compsn. contg. infinitesimal dilution of epidermal growth factor - stimulates normal cells but inhibits malignant ones and is useful in cosmetic and pharmaceutical compsns. | |
| FR2850579A1 (en) | Use of di-esters or mono-esters of cinnamic acid and derivatives of vitamin C as donors of nitric oxide in the treatment of skin, mucous membranes and scalp | |
| FR2850578A1 (en) | Use of N-benzyl or N-pyridylmethyl iminodiacetic acid derivatives as NO synthesis stimulant for treatment of conditions affecting keratinaceous and mucosal tissue | |
| FR2695557A1 (en) | Compsn. contg. infinitesimal dilution of epidermal growth factor | |
| EP0765667A1 (en) | Ribosomal fraction and composition containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20090529 |